NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced physician-reported outcomes from a large, single-center cohort of epilepsy patients treated with its OneRF Brain Ablation System at the Mayo Clinic in Jacksonville, Florida. The findings, based on 25 patients with drug-resistant focal epilepsy, highlight the potential for a paradigm shift in epilepsy treatment by combining diagnostic stereo-electroencephalography (SEEG) with radiofrequency (RF) ablation using the same implanted electrodes.
Dr. Brin Freund and the late Dr. Sanjeet Grewal led the team that performed RF ablations after diagnostic SEEG monitoring with NeuroOne electrodes. All patients were considered appropriate candidates based on anatomy and seizure localization. The physicians reported that the procedure was well tolerated, with rare short-term effects and no serious long-term complications. The majority of patients experienced meaningful reductions in seizure frequency, with some achieving sustained seizure freedom either directly after ablation or following subsequent surgical or medical therapy guided by ablation data. Most patients also reported improved quality of life and satisfaction with the procedure. Ablation targets ranged from small, discrete seizure areas to multifocal or extensively distributed epileptic networks.
Dr. Freund commented, “NeuroOne SEEG-guided radiofrequency thermocoagulation is a minimally invasive procedure that can be performed at the bedside through the same implanted diagnostic electrodes used to localize a patient's seizures. After recording seizures and mapping critical brain regions, we can precisely target seizure-generating tissue while preserving normal brain function. An important advantage is the ability to deliver a controlled, temperature-based treatment and immediately resume recording to assess effectiveness in real time. This approach has changed how we treat drug-resistant focal epilepsy and is now part of the standard of care at Mayo Clinic Florida.”
Dave Rosa, CEO of NeuroOne, stated, “These results validate our long-held belief that, for patients already undergoing diagnostic SEEG, the ability to potentially deliver meaningful therapeutic benefit through the same implanted electrodes represents a compelling clinical and economic value proposition. That opportunity is enabled by our proprietary temperature monitoring technology, which provides physicians with real-time treatment feedback and an additional layer of confidence during ablation. As the only FDA-cleared platform combining SEEG diagnosis and RF ablation using the same sEEG device, we believe NeuroOne is uniquely positioned to support this evolving diagnosis-to-therapy treatment paradigm.”
The growing real-world evidence suggests that NeuroOne's technology could reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes. The company markets four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System (for brain), and OneRF Trigeminal Nerve Ablation System. NeuroOne is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs. More information can be found at nmtc1.com.
